Publications
Discover peer-reviewed publications by therapeutic area.
The information on this page pertains to select publication resources. It is not intended to serve as a comprehensive list of all publications resources.
If you would like to discover more educational content, please use the “Search” feature.
Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
The provision of this content is not intended to recommend or suggest use of its products in any manner inconsistent with local regulatory approval. For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Acute Hepatic Porphyria (AHP)
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
Hepatology
Transthyretin Amyloidosis (ATTR)
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis
Journal of Clinical Pharmacology
Cardiovascular (CV)
Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen
Hypertension
Transthyretin Amyloidosis (ATTR)
Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study
JAMA Cardiology
Acute Hepatic Porphyria (AHP)
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
New England Journal of Medicine
Transthyretin Amyloidosis (ATTR)
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis
Circulation
Acute Hepatic Porphyria (AHP)
Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations
The Patient: Patient-Centered Outcomes Research
Transthyretin Amyloidosis (ATTR)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
New England Journal of Medicine
